Q-omics provides the consensus-scored CCDC68 profile across patient tissues and cancer cell-line models. CCDC68 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, CCDC68 is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, CCDC68 RNA expression shows 18,153 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight BRCA, COAD, and THYM as cancer lineages where CCDC68 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCDC68 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCDC68 survival associations across molecular data types. CCDC68 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (6) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCDC68 RNA expression–survival associations across cancer types. High CCDC68 expression shows unfavorable associations in CESC and LUSC, but favorable associations in BRCA, COAD, READ and UVM. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for CCDC68 RNA expression.
This table summarizes CCDC68 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 4. The strongest signals are observed in COAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for CCDC68. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCDC68 shows lower tumor expression in COAD, LUSC, THCA, LUAD and BRCA and higher tumor expression in KIRC. The COAD box plot shows higher CCDC68 RNA expression in normal versus tumor tissue (log2 FC = −2.402, t-test p < 0.001).
This table shows molecular features associated with CCDC68 in patient tissues and cancer cell lines. In patient samples, CCDC68 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, CCDC68 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BONE.
